225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient.
Omer ArasStefan HarmsenRichard TingHaluk B SaymanPublished in: Acta radiologica open (2021)
Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to 225Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive 177Lu-PSMA-617. In addition, the patient's baseline germline mutation likely predisposed him to more aggressive disease.
Keyphrases
- prostate cancer
- radical prostatectomy
- pet ct
- pet imaging
- high grade
- case report
- squamous cell carcinoma
- cancer therapy
- small cell lung cancer
- healthcare
- palliative care
- big data
- oxidative stress
- drug delivery
- deep learning
- computed tomography
- low grade
- machine learning
- rectal cancer
- dna damage
- data analysis
- smoking cessation